Sunesis pharmaceuticals inc. (SNSS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities
Net loss

-23,330

-26,615

-35,458

-

-

-

-

-

-

-

-

Net loss

-

-

-

-38,023

-36,676

-43,002

-34,598

-43,951

-20,141

-24,587

-40,226

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

1,749

2,637

3,033

4,791

6,345

6,219

-

-

-

-

1,340

Accretion of investment discounts and depreciation

-70

9

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

3,885

2,724

1,388

877

-

Depreciation and amortization

-

-

9

11

27

29

20

31

56

150

342

Amortization of debt discount and debt issuance costs

116

192

269

359

135

367

621

400

56

-

0

Write-off debt discount upon note repayment

-

-

-

27

-

-

-

-

-

-

-

Decrease in fair value of warrant liability

-

-

-

-

-3,543

-3,892

-96

-

-

-

-

(Decrease) increase in fair value of warrant liability

-

-

-

-

-

-

-

-7,509

5,878

-3,664

0

Non-cash expense related to Private Placement

-

-

-

-

-

-

-

-

-

-

21,017

Non-cash restructuring (reversals) charges, net

-

-

-

-

-

-

-

-

-

-

-1,373

Foreign exchange gain on marketable securities

-

-

-

-

-

-

142

82

-

63

0

Foreign exchange (gain) loss on marketable securities

-

-

-

-

-

-

-

-

-244

-

-

Gain on sale of property and equipment

-

-

-

-

-

-

-

11

33

82

-56

Changes in operating assets and liabilities:
Other non-cash items

-

-

-

-

-

-

-

-

-

27

0

Prepaids and other assets

294

-1,063

1,921

85

-660

43

-489

98

343

659

-434

Accounts payable

-602

-304

-174

-582

-724

2,224

875

-580

242

55

-430

Accrued clinical expense

21

-267

-667

-520

-1,158

-1,638

-699

3,079

796

444

-736

Accrued compensation

42

-497

-560

394

-681

568

254

191

261

284

192

Other liabilities

-

-

-

169

-

-

-

-

-

-

-

Other accrued liabilities

183

-622

-63

-1,062

-186

1,674

-76

522

516

564

-799

Deferred revenue

-

-

-610

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-2,441

-2,930

-5,687

-7,956

19,624

-

-

-

Net cash used in operating activities

-22,185

-24,404

-36,142

-

-

-

-

-

-22,836

-19,380

-20,183

Cash flows from investing activities
Net cash used in operating activities

-

-

-

-36,962

-38,731

-43,181

-37,423

-10,642

-

-

-

Purchases of property and equipment

-

-

26

-

-

48

-

-

15

64

6

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

11

34

104

391

Purchases of marketable securities

20,035

-

-

35,530

35,683

42,463

26,894

67,608

52,082

46,637

503

Proceeds from maturities of marketable securities

3,750

4,780

29,774

20,531

36,930

45,836

59,110

46,226

56,241

7,513

4,817

Net cash provided by investing activities

-

-

-

-14,999

1,247

3,325

32,216

-21,371

-

-

-

Net cash provided by investing activities

-16,285

4,780

29,748

-

-

-

-

-

4,178

-39,084

4,699

Cash flows from financing activities
Proceeds from notes payable, net of issuance cost

5,453

-

-

15,000

-

-

-

14,982

9,625

-

0

Principal payments on notes payable

7,500

-

7,615

7,983

1,642

9,356

7,182

-

-

-

-

Payment of financing fees and debt issuance costs

-

-

-

266

-

-

-

-

-

-

-

Proceeds from issuance of convertible preferred stock offering, net

12,533

-

4,633

5,592

16,459

-

-

-

-

-

-

Proceeds from issuance of common stock, net

32,022

-

13,877

20,367

8,709

-

-

-

-

-

-

Proceeds from issuance of common stock and warrants

-

-

-

-

-

40,024

-

-

-

-

-

Proceeds from issuance of common stock through controlled equity offering facilities, net

464

6,040

14,179

269

18,125

14,292

11,986

17,620

4,053

27,488

0

Proceeds from exercise of stock options and stock purchase rights

63

303

241

-

-

-

-

-

-

-

-

Fair value of warrants issued in connection with royalty agreement

-

-

-

-

-

-

-

3,122

-

-

-

Proceeds from exercise of warrants, stock options and stock purchase rights

-

-

-

152

533

1,961

584

1,918

-

-

-

Net cash provided by financing activities

-

-

-

33,131

42,184

46,921

5,388

37,642

-

-

-

Proceeds from issuance of common stock in third closing of Private Placement, net

-

-

-

-

-

-

-

-

-

26,713

0

Proceeds from issuance of common stock and warrants in 2010 Offering, net

-

-

-

-

-

-

-

-

-

14,218

0

Proceeds from issuance of convertible preferred stock and warrants in Private Placement, net

-

-

-

-

-

-

-

-

-

-

13,433

Proceeds from exercise of warrants, stock options and stock purchase rights

-

-

-

-

-

-

-

-

68

9

13

Net cash provided by financing activities

43,035

6,343

25,315

-

-

-

-

-

13,746

68,428

13,446

Net increase in cash, cash equivalents and restricted cash

4,565

-13,281

-

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information
Interest paid

695

790

1,066

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash activities
Interest paid

-

-

-

1,239

631

1,221

2,006

1,165

109

-

1

Transfer of fair value of exercised warrants to additional paid-in capital

-

-

-

-

100

496

43

1,715

-

-

-

Conversion of preferred stock to common stock

21,762

-

2,268

3,243

-

-

-

-

-

60,005

0

Right-of-use assets obtained in exchange for new operating lease liabilities

1,362

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

18,921

-18,830

4,700

7,065

181

5,629

-4,912

9,964

-2,038

Fair value of warrants issued in connection with notes payable

-

-

-

536

-

-

-

770

371

-

0

Commitment shares issued as cost of equity financing

-

448

-

-

4,486

9,337

-

-

-

-

-

Legal expenses accrued as cost of equity financing, net of adjustments

-

39

-

-

-

-

-

-

-

-

-

Deemed distributions to preferred stockholders

-

-

-

-

-

-

-

-

-

-

27,563

Beneficial conversion feature on preferred stock

-

-

-

-

-

-

-

-

-

-

1,188

Cashless exercise of warrants

-

-

-

-

-

-

-

402

-

3,064

440